Last updated: 03/13/2025 09:02:18

Cost-effectiveness analysis of intranasal corticosteroid in allergic rhinitis with ocular symptom

GSK study ID
219325
See study documents
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Cost-effectiveness analysis and meta-analysis of Fluticasone furoate compared with Mometasone, Budesonide, and Triamcinolone in allergic rhinitis with ocular symptoms
Trial description: This study aims to inform clinical decision-makers in managed care organizations about the relative cost-effectiveness of intranasal corticosteroids (INCS) for allergic rhinitis with ocular symptoms.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Incremental cost-effectiveness ratio (ICER) of intranasal steroid

Timeframe: Up to 1 year

Net monetary benefit (NMB) of intranasal steroid

Timeframe: Up to 1 year

Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
0
Primary completion date:
2022-01-12
Observational study model:
Cohort
Time perspective:
Retrospective
Clinical publications:
Chadakan Yan, Phichayut Phinyo, Bussakorn Mahakkanukrauh, Torsak Bunupuradah, Manish Verma, Abhay Phansalkar, Bhumika Aggarwal. Meta-analysis and cost-effectiveness analysis of intranasal corticosteroid treatment in allergic rhinitis with ocular symptoms. Asian Pacific journal of allergy and immunology. 2023-Dec;41(4): 263-272. DOI:10.12932/AP-070823-1669 PMID: 37874315
Medical condition
Rhinitis, Allergic, Perennial and Seasonal
Product
mometasone
Collaborators
Not applicable
Study date(s)
November 2022 to December 2022
Type
Observational
Phase
Not applicable

Participation criteria

Sex
Female & Male
Age
Not applicable
Accepts healthy volunteers
No
  • Participants enrolled in published randomized (parallel group) placebo-controlled trials.
  • Participants with any age; Children (aged less than [<] 12 years) and adolescents-adults (aged greater than or equals to [>=] 12 years).
  • Non-English, not available full article access.
  • Participants enrolled in non-randomized controlled trials (non-RCT), cross-over designs trials with other co-interventions were excluded (intranasal corticosteroids, antihistamines, anti-leukotrienes).
Inclusion and exclusion criteria
Inclusion criteria:
  • Participants enrolled in published randomized (parallel group) placebo-controlled trials.
  • Participants with any age; Children (aged less than [<] 12 years) and adolescents-adults (aged greater than or equals to [>=] 12 years).
  • Confirmed diagnosis of allergic rhinitis by the clinical history or the allergen identified and sensitivity proven by positive skin prick test.
  • Included any ocular outcome measurement: reflective total ocular symptoms scores (rTOSS) (Average score of Ante meridiem: Before noon [AM] + Post meridiem: After noon [PM]), instantaneous total ocular symptoms scores (iTOSS) (Predose 24 hours), Total Ocular symptoms scores.
  • Participants using recommended dose for each INCS.
Exclusion criteria:
  • Non-English, not available full article access.
  • Participants enrolled in non-randomized controlled trials (non-RCT), cross-over designs trials with other co-interventions were excluded (intranasal corticosteroids, antihistamines, anti-leukotrienes).
  • Small sample size RCT (n<10).

Trial location(s)

This study does not involve prospective enrollment of participants.

Study documents

Study report synopsis
Available language(s): English
Download document(s)
Protocol
Available language(s): English
Download document(s)
Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Study complete
Actual primary completion date
2022-01-12
Actual study completion date
2022-01-12

Plain language summaries

Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website